Liposomal Bupivacaine for Pain Control After Total Shoulder Arthroplasty
Completed · Not applicable
Conditions studied: Osteoarthritis, Arthropathy, Shoulder Pain, Closed Fracture Proximal Humerus, Four Part
In brief
This study will compare interscalene nerve block versus liposomal bupivacaine (Exparel) for pain control after total shoulder replacements. Each method will be assessed in terms of post operative pain scores, pain medication consumption, length of stay, complications (nerve injuries, hematomas, cardiac/respiratory events) and rate of readmission due to pain. The aims of this study will be achieved through a randomized controlled trial and cost-effectiveness analysis.
Key facts
- Study ID
- NCT02762071
- Run by
- Johns Hopkins University
- People needed
- 108
- Starts
- 2016-04-01
- Expected to finish
- 2019-04-15
- Last updated by the study team
- 2020-03-30
Who can join
Age: 20 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Degenerative changes of the shoulder joint (documented by radiographs) in patients planning total joint replacement with one of the study's four fellowship-trained orthopaedic surgeons.
- Patients who require revision surgeries, hemiarthroplasties, or who have chronic pain issues will be included.
You may not qualify if…
- Allergy to liposomal bupivacaine
- Contraindications to the interscalene nerve block such as:
- Preexisting neurologic defects
- Local anesthetic allergy
- Coagulopathy
- Contralateral phrenic nerve dysfunction
- Severe chronic obstructive pulmonary disease
Where it is running
- Johns Hopkins University — Columbia, Maryland, United States
- University of Texas Southwestern Medical Center — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.